Prolonged response to trabectedin in a patient with carcinosarcoma of the ovary refractory to adjuvant platinum-taxane

Abstract

Background: Carcinosarcoma of the ovary carries an unfavorable prognosis and the optimal chemotherapeutic regimen for this disease is yet to be determined. To the authorś knowledge, this is the first report of a metastatic ovarian carcinosarcoma successfully treated with trabectedin monotherapy after failure of platinum/taxane-based therapy. Case report: The case of a platinum-refractory advanced ovarian carcinosarcoma in a 73-year-old female is presented. After initial tumor debulking, the patient received adjuvant carboplatin and paclitaxel. After 2 cycles, tumor progression occurred. The authors speculated that rapid tumor progression occurred as a consequence of regrowth of sarcomatous elements within the carcinosarcoma. This platinum-refractory disease was treated with single-agent trabectedin 1.5 mg/m2 every three weeks. A prolonged partial response for 13 months along with an acceptable safety profile was achieved. During this time, the patient was able to perform her daily activities without restrictions. Conclusion: Our case suggests that trabectedin monotherapy may represent a viable therapeutic option for patients with platinum-refractory advanced ovarian carcinosarcoma.